The differentiation of anti-BCMA CAR-natural killer (NK) cells (FT576) from CD38-knockout hiPSCs that expressed anti-BCMA chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF) is currently undergoing Phase 1 clinical trial (NCT 05182073) for the treatment of multiple myeloma (Wang X. et al., 2022). This evidence concerns the gene IL15 and plasma cell myeloma.